Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015   Inocucor Technologies Inc ... biological accelerators for farmers, has received a notice ... Office for its patent application to protect Inocucor ... growth and enhance yields on farms and in ... Inocucor,s live IN-M1 microbial consortium and its fermentation ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... its international sales network Monday. The venture will bring the world’s most efficient ... Florida provides state-of-the-art equipment and technologies to both the industrial and municipal markets. ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, Inc. ... 8,000 clinics have submitted over 100,000 specimens to IDEXX ... just the first 10 days since the breakthrough kidney ... (CKD) is a leading cause of suffering and death ... specimens are consistent with generally accepted kidney disease prevalence ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... your hard disk starts screeching and you haven,t backed up your ... the past thanks to research into a new kind of computer ... at IBM Research,s Zurich lab have made new advances in researching ... the standard method of storing information on home computers. ...
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... hepatitis C programs at the Canaccord Adams Hepatitis C Conference ... InterContinental The Barclay New York Hotel in New York City.The ... under "Calendar of Events" in the Idenix Investor Center at ...
... to Find Partner to Co-Develop Company,s Chinese Patented ... April 3 Sinobiopharma, ... is pleased to announce that it ... international marketing organization headquartered in New Jersey that ...
Cached Biology Technology:Beating the back-up blues 2Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier 2
(Date:7/2/2015)... June 25, 2015 Research ... the "Next Generation Biometrics Market by Application, Technology, ... report to their offering. The next generation ... 2020, at a CAGR of 17.9% between 2015 and ... application for the market. Safran SA ( ...
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... an ongoing effort to mirror the ability of biological ... scientists from the McGowan Institute for Regenerative Medicine have ... both biological and chemical toxins. They described the findings ... biological principles to create materials that can do many ...
... University of Florida engineering researchers have found they can ... say opens the door to a wave of new technologies ... about the research appears in this week,s advance online edition ... Ben Koopman and Brij Moudgil say they used lasers not ...
... from the Robertson Foundation to create a state-of-the-art Translational ... cell therapy research and treatment programs for children and ... suffered at birth. In making the announcement, Victor J. ... Chief Executive Officer for Duke University Health System, said ...
Cached Biology News:Multifunctional polymer neutralizes both biological and chemical weapons 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 2Engineers: Weak laser can ignite nanoparticles, with exciting possibilities 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Anti-hamster Ig HRP detection kit...
...
...
Biology Products: